$DD

Director at DuPont (NYSE: DD) gets stock grant priced at $136.98 a share

DuPont (DD) reported that director Frederick M. Lowery received a stock grant of 282.888 shares at $136.98 per share on 2026-08-28. His total direct holdings increased to 13,862.3372 shares, including dividend reinvestments. The grant was valued at approximately $39,000.

Original reporting
Published Sep 1, 2026, 9:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 7:24 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$DD
Neutral
high confidence
Mentioned
$DD
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$DDNeutralLow
01

Why it matters

The grant adds modest shares to the director's stake, with negligible price impact.

02

Market read

Routine insider grant; low trading relevance.

03

What to watch

Potential cumulative effect of multiple insider grants over time.

Relevance 4/10Novelty 4/10Timing: grant disclosed on 2026-08-28

Background

Form 4 filing reports insider transactions; this grant is a routine compensation event for a director.

Company-level read

Ticker impact

$DDNeutralHigh confidence
Context

Director Frederick M. Lowery received a grant of 282.888 shares at $136.98 per share on 2026-08-28, increasing his holdings to 13,862.3372 shares.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

The grant value is about $39k, well below thresholds that affect market perception.

Market effects

None; insider grant does not affect the chemicals sector.

None; limited to DuPont shareholders.

None; no broader market effect.

Counterpoint

Even small insider grants can signal confidence; watch for future insider activity.

Key entities

  • Frederick M. Lowery

    DuPont director receiving the grant.

  • DuPont de Nemours, Inc.

    Issuer of the common stock grant.

Related articles

$DDMed

DoubleDragon off to roaring start in H1

DoubleDragon Corp. reported H1 core net income up 162% to PHP 2.41 billion and revenues up 23% to PHP 8.55 billion, citing faster core revenue growth as it shifts from fair value gains to recurring operating income. It plans multiple mall, warehouse, and Hotel101 openings in H2 and a SGD 300 million REIT vehicle for Hotel101 projects.

$DDMed

Bonta accuses DuPont of corporate shell game to dodge PFAS cleanup in California

California Attorney General Rob Bonta filed an amended complaint alleging DuPont and related spin-offs used corporate restructurings to shift PFAS cleanup liabilities and keep assets out of reach. The filing targets New DuPont, Corteva, Chemours and Qnity Electronics, citing a 2015 Chemours spin-off, a $4 billion PFAS liability cap, and alleged insurance asset transfers. The case remains active in U.S. District Court.

$DDMed

California alleges DuPont used spin-off companies to avoid PFAS liability

California Attorney General Rob Bonta alleges in a federal filing that DuPont and three spin-offs used memorandums of understanding to shift most PFAS liabilities onto Chemours while limiting exposure for Corteva, New DuPont and Qnity. Bonta cites possible fraudulent transfer law violations. DuPont disputes; a prior New Jersey case settled for $2 billion.

$DDMedAI 8/10

New Jersey secures up to $2.5 billion from DuPont, 3M for PFAS cleanup

New Jersey will receive up to $2.5 billion from settlements with DuPont and 3M over PFAS environmental damages, according to The Philadelphia Inquirer. Judge Renée Marie Bumb approved agreements ending a case filed in 2019. 3M to pay $400m-$450m; DuPont-related entities $875m over 25 years, plus $1.2b remediation commitments.

$DDMedAI 8/10

DuPont (DD) Q2 2026 Earnings Call Transcript

DuPont (DD) reported Q2 2026 net sales of $1.8 billion, up 4% year over year, with organic sales growth of 4%. Operating EBITDA was $448 million, up 5.9%, and operating EBITDA margin rose to 24.6%. Adjusted EPS was $1.88, up 48%. The company raised full-year operating EBITDA guidance and plans a $250 million share repurchase program.